KR20010085407A - Ｔｐｌ-２/ｃｏｔ 키나제 및 그의 사용 방법 - Google Patents

Ｔｐｌ-２/ｃｏｔ 키나제 및 그의 사용 방법 Download PDF

Info

Publication number
KR20010085407A
KR20010085407A KR1020017002091A KR20017002091A KR20010085407A KR 20010085407 A KR20010085407 A KR 20010085407A KR 1020017002091 A KR1020017002091 A KR 1020017002091A KR 20017002091 A KR20017002091 A KR 20017002091A KR 20010085407 A KR20010085407 A KR 20010085407A
Authority
KR
South Korea
Prior art keywords
tpl
compound
polypeptide
activity
test compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020017002091A
Other languages
English (en)
Korean (ko)
Inventor
하미쉬 존 알렌
리차드 우드워드 딕슨
조안 사라 카멘스
디넬리 위크라마신게
야준 주
모니카 폴리도로 벨리치
르랜드 헤리스 존스톤
스티븐 찰스 레이
안드레스 살메론
Original Assignee
스타르크, 카르크
바스프 악티엔게젤샤프트
플럼톤 게빈 마이클, 마틴 알 우드
메디칼 리서취 카운실
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817930.2A external-priority patent/GB9817930D0/en
Priority claimed from GBGB9827712.2A external-priority patent/GB9827712D0/en
Application filed by 스타르크, 카르크, 바스프 악티엔게젤샤프트, 플럼톤 게빈 마이클, 마틴 알 우드, 메디칼 리서취 카운실 filed Critical 스타르크, 카르크
Publication of KR20010085407A publication Critical patent/KR20010085407A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
KR1020017002091A 1998-08-18 1999-08-13 Ｔｐｌ-２/ｃｏｔ 키나제 및 그의 사용 방법 Abandoned KR20010085407A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9817930.2A GB9817930D0 (en) 1998-08-18 1998-08-18 Pathway
GB9817930.2 1998-08-18
GB9827712.2 1998-12-16
GBGB9827712.2A GB9827712D0 (en) 1998-12-16 1998-12-16 Pathway
PCT/US1999/018543 WO2000011191A2 (en) 1998-08-18 1999-08-13 Tpl-2/cot kinase and methods of use

Publications (1)

Publication Number Publication Date
KR20010085407A true KR20010085407A (ko) 2001-09-07

Family

ID=26314223

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017002091A Abandoned KR20010085407A (ko) 1998-08-18 1999-08-13 Ｔｐｌ-２/ｃｏｔ 키나제 및 그의 사용 방법

Country Status (22)

Country Link
US (1) US20020099169A1 (https=)
EP (1) EP1105501A2 (https=)
JP (1) JP4719831B2 (https=)
KR (1) KR20010085407A (https=)
CN (1) CN1323346A (https=)
AU (1) AU767973B2 (https=)
BG (1) BG105345A (https=)
BR (1) BR9913070A (https=)
CA (1) CA2339036A1 (https=)
CZ (1) CZ2001625A3 (https=)
HK (1) HK1041901A1 (https=)
HU (1) HUP0103797A2 (https=)
ID (1) ID28955A (https=)
IL (1) IL141355A0 (https=)
MX (1) MXPA01001747A (https=)
NO (1) NO20010786L (https=)
NZ (1) NZ510313A (https=)
PL (1) PL347137A1 (https=)
RU (1) RU2001107122A (https=)
SK (1) SK2242001A3 (https=)
TR (2) TR200100624T2 (https=)
WO (1) WO2000011191A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660906B1 (en) 2000-03-08 2003-12-09 Thomas Jefferson University Tpl2 transgenic knockout mice
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
GB0402661D0 (en) * 2004-02-06 2004-03-10 Medical Res Council TPL2 and its expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування

Also Published As

Publication number Publication date
BR9913070A (pt) 2001-05-08
PL347137A1 (en) 2002-03-25
BG105345A (en) 2001-12-31
CN1323346A (zh) 2001-11-21
ID28955A (id) 2001-07-19
AU767973B2 (en) 2003-11-27
WO2000011191A3 (en) 2000-06-08
HUP0103797A2 (hu) 2003-10-28
HK1041901A1 (zh) 2002-07-26
CZ2001625A3 (cs) 2002-02-13
TR200103840T2 (tr) 2002-06-21
RU2001107122A (ru) 2003-04-20
JP2002531058A (ja) 2002-09-24
TR200100624T2 (tr) 2001-08-21
NZ510313A (en) 2003-11-28
EP1105501A2 (en) 2001-06-13
US20020099169A1 (en) 2002-07-25
WO2000011191A2 (en) 2000-03-02
MXPA01001747A (es) 2003-06-06
IL141355A0 (en) 2002-03-10
JP4719831B2 (ja) 2011-07-06
NO20010786D0 (no) 2001-02-16
SK2242001A3 (en) 2001-10-08
AU5563399A (en) 2000-03-14
NO20010786L (no) 2001-04-17
CA2339036A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
JP6025758B2 (ja) Ｎｆａｔの制御因子
Callow et al. PAK4 mediates morphological changes through the regulation of GEF-H1
Kirsch et al. The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction
US6171781B1 (en) NF-AT polypeptides and polynucleotides
US20040101879A1 (en) Srebp pathway modulation through targeting hisrs
Iervolino et al. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins
US8809500B2 (en) Complexes comprising mammalian raptor polypeptide and mammalian mTOR polypeptide
Hirai et al. SH2 mutants of c-src that are host dependent for transformation are trans-dominant inhibitors of mouse cell transformation by activated c-src.
US20150094229A1 (en) Methods for the screening of antibacterial substances
AU767973B2 (en) TPL-2/COT kinase and methods of use
US20030219427A1 (en) TPL-2/COT kinase and methods of use
ZA200102200B (en) TPL-2/cot kinase and methods of use.
US20080199469A1 (en) Regulation and function of TPL-2
US20080026992A1 (en) Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
AU2014348780B2 (en) Biomarker for MELK activity and methods of using same
JP2008504224A (ja) Ｅｃｔ２のプレクストリン相同ドメインを含むポリペプチド、及びホスファチジルイノシトールに対するその結合特異性
CA2380507A1 (en) Compositions and methods to enhance sensitivity of cancer cells to mitotic stress
JP2000135100A (ja) 抗ウイルス剤を同定するためのアッセイ法
JP2002508180A (ja) ヒトｒａｄ１核酸、ポリペプチド、検定、治療方法および手段
JP2003512047A (ja) 新規胚中心キナーゼ細胞周期タンパク質、組成物および使用法
Bibbins Regulation of pp60 (c-src) and pp125 (FAK) by the Src SH2 domain
WO2004037858A2 (en) Nipa, a nuclear interacting partner of anaplastic lymphoma kinase, polypeptides and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040813

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20060105

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060228

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060630

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee